在原发性和二次性淋巴结膜炎中抑制-葡萄糖共运输体2的抑制
Fernando Caravaca-Fontán1, Kate Stevens2, Maite Padrón3
1Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 显著降低了患有淋巴细胞疾病的患者的蛋白尿症. 较高的BMI和血清白蛋白水平预测了更好的结果,具有良好的整体耐受性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- SGLT2 抑制剂在治疗自身免疫球性疾病中的蛋白尿的有效性在现实环境中尚未得到充分证实.
- 这项研究调查了SGLT2i在活检证明的淋巴细胞疾病患者的不同队列中的作用.
研究的目的:
- 评估SGLT2抑制剂在降低质尿症患者中的有效性.
- 确定影响蛋白尿减少的因素,并评估其对估计的膜过率 (eGFR) 的影响.
主要方法:
- 成年患者的回顾性,观察性,国际队列研究,活检证明了淋巴细胞疾病.
- 主要结局:SGLT2i启动后24小时蛋白尿的百分比减少.
- 二次结果:eGFR的变化,根据疾病类型减少蛋白尿,并实现≥30%的蛋白尿减少.
主要成果:
- SGLT2 抑制剂导致显著的蛋白尿减少 (3 个月后-35%至 12 个月后-48%),EGFR 降低最小.
- 蛋白尿症的减少在不同的淋巴细胞疾病中是一致的,并且与更高的体重指数 (BMI) 相相关.
- 血清白蛋白水平较高的基线预测了实现≥30%蛋白尿减少的更大可能性 (或白蛋白<3.5g/dL的0.53).
结论:
- SGLT2 抑制剂有效降低患有球膜疾病的患者的蛋白尿症.
- 较高的BMI和基线血清白蛋白与更好的治疗反应有关.
- 实现显著蛋白尿减少的患者经历了较慢的eGFR下降,这表明具有保护作用.
相关概念视频
Secondary Active Transport
121.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
121.1K
Glucose Transporters
22.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
Glucose Absorption Into the Small Intestine
31.8K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K
Oral Hypoglycemic Agents: Glinides
186
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
186
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211


